- Home
- TCBK vs VRDN Comparison
TCBK vs VRDN Comparison
Compare TCBK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBK
- VRDN
- Stock Information
- Founded
- TCBK 1975
- VRDN 2006
- Country
- TCBK United States
- VRDN United States
- Employees
- TCBK N/A
- VRDN N/A
- Industry
- TCBK Major Banks
- VRDN Medical Specialities
- Sector
- TCBK Finance
- VRDN Health Care
- Exchange
- TCBK Nasdaq
- VRDN Nasdaq
- Market Cap
- TCBK 1.3B
- VRDN 1.0B
- IPO Year
- TCBK N/A
- VRDN N/A
- Fundamental
- Price
- TCBK $39.90
- VRDN $13.92
- Analyst Decision
- TCBK Buy
- VRDN Strong Buy
- Analyst Count
- TCBK 6
- VRDN 12
- Target Price
- TCBK $47.80
- VRDN $38.50
- AVG Volume (30 Days)
- TCBK 87.2K
- VRDN 838.2K
- Earning Date
- TCBK 07-24-2025
- VRDN 05-06-2025
- Dividend Yield
- TCBK 3.31%
- VRDN N/A
- EPS Growth
- TCBK 4.60
- VRDN N/A
- EPS
- TCBK 3.43
- VRDN N/A
- Revenue
- TCBK $389,795,000.00
- VRDN $302,000.00
- Revenue This Year
- TCBK $7.08
- VRDN N/A
- Revenue Next Year
- TCBK $5.38
- VRDN $21,976.14
- P/E Ratio
- TCBK $11.63
- VRDN N/A
- Revenue Growth
- TCBK 1.12
- VRDN 4.86
- 52 Week Low
- TCBK $35.20
- VRDN $9.90
- 52 Week High
- TCBK $51.06
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- TCBK 50.00
- VRDN 55.94
- Support Level
- TCBK $39.51
- VRDN $13.37
- Resistance Level
- TCBK $40.49
- VRDN $14.18
- Average True Range (ATR)
- TCBK 0.82
- VRDN 0.67
- MACD
- TCBK -0.12
- VRDN 0.14
- Stochastic Oscillator
- TCBK 37.57
- VRDN 85.65
About TCBK TriCo Bancshares
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).